Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)

Trial Profile

Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2018

At a glance

  • Drugs Abicipar pegol (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MAPLE
  • Sponsors Allergan
  • Most Recent Events

    • 29 Nov 2018 According to a Molecular Partners AG media release, results are anticipated in H1 2019.
    • 01 Nov 2018 According to a Molecular Partners AG media release, MAPLE trial run by partner Allergan fully recruited in Q3 2018, testing further optimized formulation of abicipar. Results expected in H1 2019 and Allergan plans to file abicipar with FDA in H1 2019 pending pre-BLA meeting.
    • 01 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top